ArticleTransboundary and emerging diseases2026
Characterization of Host Protein Prohibitin-2 Interacting With Cryptosporidium parvum Cyclophilin 23.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of Host Protein Prohibitin-2 Interacting With Cryptosporidium parvum Cyclophilin 23.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cryptosporidium parvum is a prevalent protozoan pathogen responsible for moderate to severe diarrhea in humans and animals, posing a significant threat to global public health. Host-parasite interactions play a crucial role in the infection process of C. parvum. Cyclophilin 23 (CpCyP23), a secreted protein of C. parvum, is implicated in parasite development and pathogenicity. As a secretory protein, its function often relies on interactions with host cell proteins. However, it remains unclear whether CpCyP23 has host interaction partners and what specific roles such interactions play during infection. In this study, using CpCyP23 as bait, we screened for potential interacting proteins in HCT-8 cells through pull-down assays combined with mass spectrometry (MS) analysis. The interaction was subsequently confirmed by co-immunoprecipitation (Co-IP) and bimolecular fluorescence complementation (BiFC) assays. Immunofluorescence (IF) was employed to determine subcellular localization. Furthermore, after confirming the altered expression of the interacting protein during parasite infection, we analyzed its impact on parasite infection using small interfering RNA (siRNA) knockdown and overexpression techniques, coupled with parasite infection assays. The results identified the host cell protein Prohibitin-2 (PHB2) as an interacting partner of CpCyP23. Co-IP and BiFC assays validated their interaction, and IF revealed their colocalization in the cytoplasm of HCT-8 cells. The mRNA level of PHB2 was significantly upregulated at 3 and 12 h postinfection (hpi) with C. parvum. Functional experiments further demonstrated that the expression level of PHB2 positively correlates with the infection burden of C. parvum. In summary, this study reveals an interaction between the host cell protein PHB2 and CpCyP23 and identifies PHB2 expression level as a key host factor significantly influencing C. parvum infection. These findings provide experimental evidence and a potential target for elucidating the pathogenic mechanisms of C. parvum and developing novel anti-infection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.